Antireflux covered metal stent for nonresectable distal malignant biliary obstruction: a multicenter randomized controlled trial

Abstract

Background and Aim

An antireflux metal stent (ARMS) for nonresectable distal malignant biliary obstruction may prevent recurrent biliary obstruction (RBO) due to the duodenobiliary reflux and prolong time to RBO (TRBO). The superiority of the ARMS over conventional covered self‐expandable metal stents (SEMSs) has not been fully examined.

Methods

We conducted a multicenter randomized controlled trial to examine whether TRBO of an ARMS with a funnel‐shaped valve was longer than that of a covered SEMS in SEMS‐naïve patients. Secondary outcomes included causes of RBO, adverse events, and patient survival.

Results

We enrolled 104 patients (52 patients per arm) at 11 hospitals in Japan. The TRBO did not differ significantly between the ARMS and covered SEMS groups (median, 251 vs. 351 days, respectively; P = 0.11). RBO due to biliary sludge or food impaction was observed in 13% and 9.8% patients who received an ARMS and covered SEMS, respectively (P = 0.83). The ARMS was associated with a higher rate of stent migration compared with the covered SEMS (31% vs. 12%, P = 0.038). The overall rates of adverse events were 20% and 18% in the ARMS and covered SEMS groups, respectively (P = 0.97). No significant between‐group difference in patient survival was observed (P = 0.26).

Conclusions

The current ARMS was not associated with longer TRBO compared with the covered SEMS. Modifications including addition of an anti‐migration system are required to use the current ARMS as first‐line palliative treatment of distal malignant biliary obstruction (UMIN‐CTR clinical trial registration number: UMIN000014784).

This article is protected by copyright. All rights reserved.

https://ift.tt/2TgcGX7